Protalix BioTherapeutics (PLX) Posts Quarterly Earnings, Misses Estimates By $0.01 EPS
Protalix BioTherapeutics (NYSE:PLX) released its earnings data on Thursday. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01, Stock Ratings Network.com reports.
Protalix BioTherapeutics (NYSE:PLX) opened at 3.86 on Thursday. Protalix BioTherapeutics has a 52 week low of $3.70 and a 52 week high of $5.72. The stock’s 50-day moving average is $4.15 and its 200-day moving average is $4.36. The company’s market cap is $357.8 million.
PLX has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. On the ratings front, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50. Finally, analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.